ArticleOpen forum infectious diseases2024
One-Year Frailty Transitions Among Persons With HIV Aged 70 Years or Older on Antiretroviral Treatment.
Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Frailty phenotype transitions and functional improvements during a supervised exercise trial in older people with HIV: results from the HEALTH Trial.Age and ageing · 2026Trial
- Comparison of four frailty scores to predict adverse health events and mortality in people living with HIV aged 70 years and more (ANRS EP 66 SEPTAVIH study).HIV medicine · 2026Article
- QR Code-Enabled Self-Access Lifestyle Education in Older People Living With HIV: Pragmatic Pilot Quasi-Experimental Pretest-Posttest Implementation Study.Journal of medical Internet research · 2026Article
- Predictors of Cerebral Small-Vessel Disease in Middle-Aged, Virologically Controlled People Living With HIV.Open forum infectious diseases · 2026Article
- Frailty and All-Cause Mortality Among People With HIV Engaged in Clinical Care in the United States.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- Frailty Transition Among Older Adults Living With HIV in Thailand: A 5-Year Longitudinal Study.Journal of the International AIDS Society · 2026Observational
- Geriatric syndromes in women living with HIV.Current opinion in HIV and AIDS · 2026Review
- Distinct Defects in Marginal Zone B Cells and Filtration Function Characterize Hyposplenism in Persons With HIV-1 on Prolonged ART.Open forum infectious diseases · 2025Article
- Predictors of frailty trajectories among people with HIV.AIDS (London, England) · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: People with HIV (PWH) are aging. Frailty is an age-related condition predictive of hospitalization and mortality. Here, we assessed the frequency and factors associated with frailty transitions at 1-year follow-up in elderly PWH. Methods: Five hundred eight PWH aged 70 years or older who were on antiretroviral treatment were included in the French multicenter SEPTAVIH study in 2019-2020. Participants were classified as robust, prefrail, or frail according to Fried frailty phenotype at baseline and at 1 year. Logistic regression models were used to evaluate socioeconomic and medical factors associated with transition between frailty states. Models were adjusted for gender, age at baseline, education, and period of HIV diagnosis (before vs after 1996). Results: Seventeen PWH died during the 1-year follow-up. Of the remaining 491 PWH (median age, 73 years), frailty status worsened for 18% of participants and improved for 14% at 1 year. Advanced age, baseline CD4+ T-cell count <350 cells/mm Conclusions: Preventing frailty in elderly PWH is a long-term problem, beginning with the early diagnosis of HIV infection and the management of comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.